This study is the first prospective study to assess the prevalence, epidemiology, and risk factors of HIV-1 drug resistance in newly diagnosed HIV-infected patients in Belgium. In January 2003 it was initiated as part of the pan-European SPREAD program, and continued thereafter for four inclusion rounds until December 2006. Epidemiological, clinical, and behavioral data were collected using a standardized questionnaire and genotypic resistance testing was done on a sample taken within 6 months of diagnosis. Two hundred and eighty-five patients were included. The overall prevalence of transmitted HIV-1 drug resistance in Belgium was 9.5% (27/285, 95% CI: 6.6-13.4). Being infected in Belgium, which largely coincided with harboring a subtype B virus, was found to be significantly associated with transmission of drug resistance. The relatively high rate of baseline resistance might jeopardize the success of first line treatment as more than 1 out of 10 (30/285, 10.5%) viruses did not score as fully susceptible to one of the recommended first-line regimens, i.e., zidovudine, lamivudine, and efavirenz. Our results support the implementation of genotypic resistance testing as a standard of care in all treatment-naive patients in Belgium. 355 
INTRODUCTION D

OCUMENTATION OF BASELINE HUMAN IMMUNODEFICIENCY
VIRUS (HIV) drug resistance has improved over the past 5 years. Publications in different geographic settings report a prevalence of transmitted drug resistance (TDR) ranging from 3.3% to 24.1%. [1] [2] [3] Recently, a prospective study in 17 European countries found an overall prevalence of 9.1%. 4 However, comparisons are hard to make since no uniform mutations list or interpretation algorithm is used for the estimation of TDR. Therefore, Shafer and colleagues 5 proposed a provisional list of criteria for selecting TDR mutations. However, in addition to transmitted resistance as defined by the criteria set by Shafer et al., 5 all mutations associated with resistance or altering the genetic barrier-the number of mutations necessary for loss of susceptibility-should be considered for predicting the impact of resistance on first line treatment. For this, clinically validated algorithms for the interpretation of HIV-1 genotypic drug resistance information should be used. 6 Surveillance of TDR gives valuable information since it informs public health authorities on the need for routine HIV-1 drug resistance testing in drug-naive patients in order to increase the chances for a successful first line treatment. Also, it should urge public health authorities to design targeted and more efficient infection prevention programs in order to limit the further spread of resistant HIV-1. Moreover, TDR can persist over time 7, 8 and untreated persons can be infected with a resistant virus without knowing so, and possibly spread resistance even further. 9 The last published European guidelines recommend genotypic resistance testing for all drug-naive patients with acute or recent HIV-1 infection while for chronically infected patients resistance testing is advised only if the prevalence of TDR exceeds 10% for phenotyping or 5% for genotyping. 10 A more recent update extends resistance testing to include all drug-naive patients (http://www.kuleuven.be/rega/cev/links/european_drug_guidelines/index.htm), while a new study documented the cost effectiveness of genotypic resistance testing of drug-naive patients as soon as the TDR reaches 1%. 11 To date, only two studies on baseline drug-resistant HIV-1 in Belgium have been published. 12, 13 Derdelinckx and colleagues reported retrospectively a prevalence of TDR in 2000 of 7.2% (6/83; 95%CI: 3.4-14.9%) based on the International AIDS Society-USA list of mutations of 2003. 13 Van Vaerenbergh et al. used a line-probe resistance assay and achieved retrospectively a prevalence of 29% (67/231; 95% CI: 23.5-35.2%) on average for the period 1995-1998. 12 Our study was the first prospective study estimating the prevalence of drug resistance in newly diagnosed patients in Belgium and covered the period [2003] [2004] [2005] [2006] in which a specialized list of mutations that can be regarded as genuine markers of TDR was used. Furthermore, the epidemiology and potential risk factors for HIV-1 drug resistance were investigated.
MATERIALS AND METHODS
Patients
All eight Belgian AIDS Reference Centers-Université de Liège (ULG, Liège), Universitair Ziekenhuis Leuven (KUL, Leuven), Centre Hospitalier Universitaire Saint-Pierre (CHU St.-Pierre, Brussels), Instituut voor Tropische Geneeskunde (ITG, Antwerp), Universitair Ziekenhuis Gent (UG, Gent), Universitair Ziekenhuis Brussel (UZ Brussel, Brussels), Université Catholique de Louvain (UCL, Brussels), and Université Libre de Bruxelles (ULB, Brussels)-collaborated in this study as part of the pan-European SPREAD study (http://www.spread-europe.org). 4 Based upon a power analysis for the European study, a sample size of 70 was assigned to Belgium. An oversampling of 10% was considered as some patients would probably be excluded according to predefined inclusion criteria. These criteria were age older than 18 years, a viral load above 1000 copies/ml, not having received any antiretroviral drug, and a sample available within 6 months of diagnosis. Inclusion started in January 2003 and ended in December 2006. In total, 280 patients (4 times 70) were estimated to be included. Based on a first preliminary report indicating that the prevalence of TDR in Belgium in 2003 was 8.2% (6/73, 95% CI: 3.8-6.8), 14 a sample size of 280 should have a power of 70% to show whether or not the true prevalence of TDR was significantly higher than the 5% cost-effective cut-off mentioned in the European guidelines at that time. 10, 15 For each inclusion round, the required number of patients was stratified for the different centers weighted to the number of patients newly diagnosed in the previous year in that center. Epidemiological, clinical, and behavioral data were collected using a standardized questionnaire. 4 The first measurements of viral load and CD4 counts were collected. When a patient was thought to be directly epidemiologically linked to another included patient, this was notified and one extra patient from that center was included. By consulting the National Database at the Scientific Institute of Public Health (Brussels, Belgium) containing anonymous demographic information on all patients diagnosed with HIV-1 in Belgium, it could be confirmed that the included patients were not diagnosed with HIV-1 in previous years or that a patient was not included more than once. Moreover, the representative nature of the collected sample for the Belgian epidemic could be investigated by comparing some of the basic characteristics (sex, country of origin, and route of infection) of the studied population to the data gathered in the Belgian National Database in the period between 2003 and 2006. Finally, patterns of drug resistance were compared to the patterns occurring in viral isolates of patients followed at KUL (Leuven) and failing treatment.
Sample processing, resistance, and phylogenetic analysis
Ethical approval was obtained at all centers and patients needed to provide informed consent before inclusion. Blood samples were taken within 6 months of diagnosis. Populationbased nucleotide sequencing of the reverse transcriptase (RT) and protease (PRO) gene was performed at KUL using the ViroSeq HIV-1 Genotyping System (version 2) (Celera Diagnostics, Alameda, CA) or an in-house assay upon failure of the first method 16 (EMBL/GenBank accession numbers EU248291-EU248588). The sequence alignments are available on request. TDR was defined as the presence of at least one mutation of the list of drug-resistance mutations proposed by Shafer et al. 5 The Rega algorithm (version 6.4.1) was used to determine the susceptibility of the virus to the different antiretroviral drugs (freely accessible at http://hivdb.stanford.edu/pages/asi/). 6, 17 The subtypes were determined by use of the REGA HIV-1 subtyping tool v.2.0. 18 (available at http://www.bioafrica.net/virusgenotype/html/index.html or http://www.kuleuven.be/rega/cev/ default.htm). To investigate whether some samples belonged to naive transmission clusters, phylogenetic analysis was performed.
Statistical data analysis
The data were analyzed using the statistical software R (version 2.3.1). Prevalence values were calculated with a 95% Wilson score confidence interval based on a binomial distribution.
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Categorical data were compared using the chi-square test, Fisher's exact test, or logistic regression techniques. Continuous data were investigated by means of a t-test, the Mann-Whitney U test, or linear regression.
RESULTS
Characterization of the study population
Among the 307 newly diagnosed HIV-1-infected patients enrolled in the study, 22 (7.2%) were excluded as a result of predefined criteria. Seven of these were excluded because no sample was available within 6 months of diagnosis. For one patient there was no viral load above 1000 copies/ml. By consulting the National Database at the Scientific Institute of Public Health, nine patients were judged to be already diagnosed with HIV-1 before the start of this study. Finally, sequence analysis was successful for more than 98 % (302/307) of the patient samples. As a result, 285 patients were included for further anal- Table 1 . At the time of diagnosis men were significantly older than women (median age: 37 and 31 years, respectively, p Ͻ 0.001). The majority of the West-European patients (78%) were men who have sex with men (MSM), whereas most (89%) of the patients originating from Sub-Saharan Africa were infected through heterosexual contact. Anonymous sex was playing a considerable role in the transmission of HIV-1 (35%). Among MSM this was significantly more often the case than among heterosexuals (47% versus 23%, OR: 2.9, 95% CI: 1.7-5.3, p Ͻ 0.001). From all patients who were sexually infected, 6% (16/265) knew at the time of infection that the source was HIV-1 positive. Almost all (14/16; 87%) of these patients were MSM. Coinfection with hepatitis B (acute or chronically) was more frequent among persons who originated from or were infected in a high prevalence country (44% versus 27%, OR: 2.1, 95% CI: 1.2-3.7, p ϭ 0.007). Sexually transmitted diseases, especially syphilis and gonorrhea, were more frequently seen in MSM (OR: 3.1, 95% CI: 1.7-5.8, p Ͻ 0.001). The viral load was significantly lower in women than in men (4.48 versus 4.70 log 10 HIV RNA copies/ml, p ϭ 0.008). The CD4 count was significantly higher in MSM than in other risk groups (469 versus 345 cells/mm, p Ͻ 0.001).
Subtypes
Slightly more than half of the patients harbored a subtype B virus (166/285, 58.2%). CRF02_AG (circulating recombinant form) was identified in 30 cases (10.5%). Other subtypes were A (9.8%), C (8.0%), G (2.5%), and less frequently (Ͻ1%): CRF06_cpx, CRF13_cpx, D, H, and J. Eight percent could not be classified into one specific subtype or CRF and were specified as URF (unique recombinant form). The subtyping was not possible for two sequences. Being infected with a subtype B strain was linked to transmission through MSM (OR: 37.9, 95% CI: 18.6-82.3, p Ͻ 0.001). Furthermore, viruses with non-B subtypes were significantly more prevalent in people originating from or infected in a high prevalence country (OR: 323.3, 95% CI: 53.3-12218.0, p Ͻ 0.001).
Prevalence and patterns of resistance
The overall prevalence of TDR within newly diagnosed patients in Belgium was 9.5% (27/285, 95% CI: 6.6-13.4) ( Table  2 ). The prevalence of mutations associated with transmitted nucleoside reverse transcriptase inhibitor (NRTI) resistance was 7.0% (20/285, 95% CI: 4.6-10.6), with transmitted non-NRTI (NNRTI) resistance 3.5% (10/285, 95% CI: 1.9-6.3) and with transmitted protease inhibitor resistance 1.8% (5/285, 95% CI: 0.8-4.0). A revertant mutation at position 215 of RT was the most prevalent (12/27), followed by RT41L (9/27), RT103NSR (6/27), RT181C (3/27), and RT219QE (3/27) ( Table 3) . Other mutations were prevalent in less than three 
Comparison with the national database
There were significantly more men in the studied population than in the Belgian National Database (OR: 2.7, 95% CI: 2.0-3.6, p Ͻ 0.001), which contains data from all confirmed diagnoses in Belgium. This is due to the overrepresentation in the SPREAD sample of MSM (OR: 5.0, 95% CI: 3.9-6.5, p Ͻ 0.001). In this study only one patient infected through intravenous drug use was included, resulting in an underestimation of this route of infection compared to the national data (OR: 0.2, 95% CI: 0.0-0.9, p ϭ 0.04). Furthermore, there were significantly more Belgians among the study population (OR: 2.7, 95% CI: 2.0-3.5, p Ͻ 0.001). There was a high number of SubSaharan Africans in the data (66/285), although, compared to the national data set, this number is significantly lower (OR: 0.3, 95% CI: 0.2-0.4, p Ͻ 0.001).
Factors associated with resistance
TDR was identified significantly more in subtype B viruses than in non-B viruses (12.7% versus 5.1%, OR: 2.7, 95% CI: 1.0-6.9, p ϭ 0.04). The fact that a person originated from a high prevalence country did not contribute to TDR. However, being infected in Belgium significantly enhanced the risk for TDR (13.0% versus 3.6%, OR: 4.0, 95% CI: 1.1-21.6, p ϭ 0.02). Several other factors were investigated as potential risk factors for TDR: route of infection, time since diagnosis, sex with an anonymous person, the presence of sexually transmitted diseases, hepatitis B or C serology, and CDC stage. Only sex with an anonymous person turned out to be a (borderline) predictor for TDR (14.0% versus 7.0%, OR: 2.2, 95% CI: 0.9-5.2, p ϭ 0.06).
DISCUSSION
This study is the first prospective Belgian study to assess the prevalence and risk factors of drug resistance in newly diagnosed HIV-1-infected patients. Originally, in January 2003 it was started as part of the pan-European SPREAD program, and it continued for four inclusion periods until December 2006. We found that the overall prevalence of TDR in Belgium was 9.5% (6.6-13.4%). This is significantly higher than 5% (p Ͻ 0.001), which, at the time of the study design, was considered as threshold for cost-effective management using genotypic resistance testing. 15 This prevalence is in line with the one in other published cohorts of Western European countries such as Portugal 19 and Greece 20 and with the 2003 European average of 9.1% found in the SPREAD study. 4 However, comparisons of drug resistance prevalence can be misleading due to the different study designs and the different mutation lists that have been used to trace mutations. For the latter reason, the use of a standardized mutation list or algorithm is urgently needed.
Among the mutations indicative for transmission of resistance, thymidine analogue mutations (TAMs) and 215 revertants were dominant (18/27, 66.6%), which is partially a reflection of the extensive use of thymidine analogues (AZT and d4T) in mono-and dual therapies in the pre-HAART era. However, in the absence of drug selective pressure, viruses with resistance mutations have a tendency to revert to wild type because of the lower fitness of the virus carrying resistance mutations. 21 Therefore, the low impact of TAMs and 215 revertants on the replication capacity of the virus in drug-naive conditions, 22 resulting in those mutations surviving the longest in untreated patients, may also play a role. 23 Almost 1 out of 10 newly diagnosed patients in Belgium harbors TDR mutations. However, this is most probably an underestimation since several resistance mutations reduce the virus fitness such that after transmission and in the absence of therapy they tend to disappear from the majority population. 21 Furthermore, in three subtype B sequences mutations PR46L and/or RT215AL occurred, which most probably reflects transmission of resistance, though they are not considered in the list of Shafer et al. Thus, using this list may underestimate the prevalence of TDR, suggesting that minor changes to the criteria and list should be considered.
By applying the Rega algorithm, the decreased susceptibility of the virus to the available antiviral drugs and recommended first-line regimens could be studied. 24 In this respect, more than 1 out of 10 (30/285, 10.5%) viruses of newly diagnosed patients in our study did not score fully susceptible anymore to the combination of zidovudine, lamivudine, and efavirenz. Based on this reasoning, we recommend that baseline genotypic resistance testing should be the standard of care in Belgium for all newly diagnosed patients to optimize the success of initial therapy and to prevent further development of resistance and ongoing transmission. However, clinicians should be aware that such genotyping cannot provide the full picture of drug resistance. As explained above, the reported TDR can be an underestimate. Concomitantly, current genotypic assays can miss mutants in plasma if they comprise only a minority of the viral population. 25 Furthermore, interpretation algorithms for HIV-1 drug resistance must be used with caution since they are mostly based on subtype B information and incorporate only preliminary rules for new drugs. 6 The relatively high rate of baseline resistance in Belgium reveals that a large number of HIV-1-infected persons under failing treatment, and thus carrying resistance mutations, continue to engage in sexual risk behavior or that persons infected with a resistant virus, possibly unaware of their serostatus, are transmitting resistance even further. The patterns of resistance mutations in patients from our therapy-naive population, most of whom carry only one resistance mutation, are different from the patterns seen in treated patients failing therapy, almost all with multiple resistance mutations. This discrepancy does not necessarily mean that patients failing therapy are not the source of transmitted drug resistance; the lower number of mutations can result from reversion to wild type of some but not all mutations, as indicated by the large number of 215 revertants seen in our population. In this case, the patient with transmitted resistance is still carrying virus with multiple resistance mutations, and care should be taken in the choice of the first treatment regimen. However, if transmitted resistance is a result of onward transmission, as recently documented by Brenner et al. 8 and also seen by Van Laethem et al., 26 then there is no minor variant carrying more resistance mutations, and more treatment options are available for these patients. Our preliminary phylogenetic results reported here support the view that at least some transmitted resistance in Belgium is a result of onward transmission, but more profound analyses with new methods and a better study and control population are needed to quantify its impact on the epidemic. In the meantime health care workers and HIV policy makers should maintain a focus on prevention of HIV-1 transmission and should motivate persons who show risk behavior to have frequent HIV screening. In this context it is worth mentioning that on average, newly diagnosed men are older than newly diagnosed women, with many of the women being diagnosed during pregnancy, and that the duration of infection could be estimated for only 41%. Increased vigilance is thus needed, as well as continued surveillance of baseline HIV-1 resistance.
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Although in the literature there are discordant temporal trends in the prevalence of transmitted resistance, 27,28 our results do not show any significant temporal trend in any type of resistance. Since the assignment of the annual sample size was done within the scope of the pan-European SPREAD study, the sample sizes were limited, making the study powered to detect only very large differences over time. For example, the prevalence would have to increase from 7% to 30% to be able to show this statistically using annual sample sizes of 70.
TDR was more frequently identified in patients infected in Belgium and in subtype B viruses. Since both factors are associated with each other (OR: 15.9, 95% CI: 7.9-33.7, p Ͻ 0.001), the effect of subtype B on TDR is no longer significant when considering only patients infected in Belgium (15.1% versus 5.6%, OR: 3.0, 95% C.: 0.7-27.9, p ϭ 0.17). This information is epidemiologically important since it probably indicates that the effect of subtype B on the transmission of resistance cannot be attributed to specific viral characteristics of the subtype, but rather to the fact that more than half of the non-B subtypes (55%, 66/117) circulating in Belgium originate from Sub-Saharan Africa where therapy was only recently introduced. Besides subtype B and being infected in Belgium, no other risk factors for TDR were found. We cannot reject the hypothesis that TDR is persisting over time since the duration of infection did not have an impact on the prevalence of resistance-associated mutations.
Publications report plasma HIV-1 viral load to be dependent on the ethnic or genetic background of the host. 29, 30 In our population, people originating from Sub-Saharan Africa indeed have a lower viral load, but, probably due to low power, this difference was not significant (4.55 versus 4.69 log 10 HIV RNA copies/ml, p ϭ 0.13). We did find, however, that the viral load was significantly lower in women than in men and this gender effect remained significant after correction for ethnicity and center (p ϭ 0.04). The correction for center was done to avoid the impact of the use of different assays to measure viral load. We saw a higher CD4 count in MSM compared to other risk groups. This may be due to the fact that MSM undergo HIV testing more frequently and are thus diagnosed at an earlier stage of their infection. Since duration of infection could only be estimated for 41% of the patients, we could not prove this statistically: 114 days versus 131 days, p ϭ 0.53.
The data were sampled from patients being diagnosed at a Belgian AIDS Reference Center (ARC). This, however, does not guarantee a complete overview of all patients diagnosed with HIV infection, as in Belgium some patients seem not to attend these specialized ARCs for diagnosis, care, and treatment but rather go to a general practitioner or a local hospital. Moreover, clinicians reported that MSM were more frequently screened for HIV-1 infection and that nonindigenous Belgians were less prone to provide informed consent for the study. Consequently, the data were compared with the national data collected by the Belgian Scientific Institute of Public Health. This national database collects every diagnosis made in Belgium in one of the AIDS Reference Laboratories (ARL), the only laboratories providing confirmatory HIV testing in Belgium. Data are collected anonymously regardless of follow-up. When comparing our data on sex, country of origin, and route of infection to this national database, we noticed a higher percentage of MSM in our data, a lower percentage of IVDU, a higher rate of indigenous Belgians, and a lower rate of Sub-Saharan Africans. This should be taken into consideration in the generalization of the results to all newly diagnosed patients in Belgium.
In conclusion, the prevalence of transmitted resistance among newly diagnosed HIV-1-infected patients in Belgium was found to be 9.5%. We support the immediate need for routine resistance testing before initiation of antiretroviral therapy in Belgium. Being infected in Belgium (a condition largely coinciding with harboring a subtype B virus) was found to be significantly associated with transmission of drug resistance.
